# OnCo record neratinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/neratinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "neratinib" ;
  schema:name "Neratinib"@en ;
  schema:description "A pill taken for a year after trastuzumab to further reduce recurrence in HER2-positive, hormone-positive breast cancer, limited by severe diarrhoea."@en ;
  schema:url <https://onco.cc/drugs/neratinib/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Neratinib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q6995920> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Neratinib> ;
  onco:status "approved" ;
  onco:modality "Small-molecule irreversible pan-HER kinase inhibitor" ;
  schema:alternateName "Nerlynx" ;
  onco:approval "US 2017: Extended adjuvant HER2+ early breast cancer after trastuzumab", "US 2020: HER2+ metastatic breast cancer with capecitabine after ≥2 anti-HER2 regimens" ;
  onco:cancers <https://onco.cc/cancers/breast-her2-positive/>, <https://onco.cc/cancers/her2-positive-breast-brain-metastases/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/her2-tyrosine-kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/her2/>, <https://onco.cc/targets/egfr/> ;
  onco:companies <https://onco.cc/companies/puma-biotechnology/> .